Menu
ETF
Annual · values202420232022202120202019201820172016201520142013
Operating Cash Flow-4.31 M USD-5.80 M USD-7.10 M USD-6.80 M USD-2.59 M USD-3.71 M USD-5.01 M USD-4.24 M USD-2.54 M USD-2.30 M USD-2.74 M USD-2.99 M USD
Depreciation & Amortization0 USD0 USD0 USD0 USD18750 USD25000 USD25000 USD25000 USD19453 USD
Stock-Based Compensation1.51 M USD89502 USD297653 USD-104601 USD87508 USD
Capital Expenditures0 USD
Cash Flow from Investing0 USD0 USD0 USD0 USD0 USD0 USD0 USD0 USD0 USD0 USD0 USD-331377 USD
Cash Flow from Financing5.58 M USD4.28 M USD0 USD15.57 M USD2.38 M USD3.66 M USD5.08 M USD4.05 M USD3.03 M USD2.31 M USD2.24 M USD3.76 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-2.99 M USD

Zivo Bioscience Inc. is a research and development company specializing in biotechnology, with a focus on leveraging proprietary algal and bacterial strains to create innovative nutritional compounds and bioactive molecules. The company's core operations center around the study, development, and commercialization of naturally derived ingredients targeting both human and animal health. Zivo Bioscience actively develops and licenses intellectual property, including unique algae cultures, extracts, and patented or patent-pending product concepts. Its primary fields of application include human dietary supplements, nutraceuticals, food ingredients, and animal feed additives, with projects addressing areas such as poultry gut health, bovine mastitis, canine joint health, and human immune modulation. Operating across both the biotech and agtech sectors, Zivo’s business model is heavily based on licensing its technology and selling specialized bioactive compounds to manufacturers in the nutrition, supplement, and medical food industries, emphasizing the growing market demand for natural, functional ingredients.